Behcet's disease

New England Journal of Medicine

Volumn 341, Issue 17, 1999, Pages 1284-1291

  Sakane, Tsuyoshi ^a   Takeno, Mitsuhiro ^a   Suzuki, Noboru ^a   Inaba, Goro ^b  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; AZATHIOPRINE; BETAMETHASONE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; DIPYRIDAMOLE; HEPARIN; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; METHOTREXATE; METHYLPREDNISOLONE; PENTOXIFYLLINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TETRACYCLINE; THALIDOMIDE; TRIAMCINOLONE ACETONIDE; TROPICAMIDE; WARFARIN; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID;

ARTICLE; BEHCET DISEASE; CLINICAL EXAMINATION; DRUG INDICATION; GENITAL ULCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SKIN ULCER; TOPICAL DRUG ADMINISTRATION; FEMALE; MALE; REVIEW;

ANTI-INFLAMMATORY AGENTS; BEHCET SYNDROME; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE;

EID: 0033592467     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199910213411707     Document Type: Article

References (43)

1. Kastner DL. Intermittent and periodic arthritic syndromes. In: Koopman WJ, ed. Arthritis and allied conditions: a textbook of rheumatology. 13th ed. Vol, 1. Baltimore: Williams & Wilkins, 1997:1279-306.
2. Kaklamani VG, Variopoulos G, Kaklamanis PG. Behçet's disease. Semin Arthritis Rheum 1998;27:197-217.
3. Nussenblatt RB. Uveitis in Behçet's disease. Int Rev Immunol 1997;14: 67-79.
4. Nakae K, Masaki F, Hashimoto T, Inaba G, Mochizuki M, Sakane T. Recent epidemiological features of Behçet's disease in Japan. In: Wechsler B, Godeau F, eds. Behçet's disease. Amsterdam: Excerpta Medica, 1993: 145-51.
5. Zouboulis CC, Kötier I, Djawari D, et al. Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe. Yonsei Med J 1997;38:411-22.
6. Dilsen N, Konice M, Aral O, Öcal L, Inane M, Gill A. Risk factors for vital organ involvement in Behçet's disease. In: Wechsler B, Godeau F, eds. Behçet's disease. Amsterdam: Excerpta Medica, 1993:165-9.
7. Mizuki N, Inoko H, Ohno S. Pathogenic gene responsible for the predisposition to Behçet's disease. Int Rev Immunol 1997;14:33-48.
8. Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behçet's disease. Arch Ophthalmol 1982;100:1455-8.
9. Sakane T. New perspective on Behçet's disease. Int Rev Immunol 1997; 14:89-96.
10. Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int Rev Immunol 1997;14:21-32.
11. Hamuryudan V, Yurdakul S, Özbakir F, Yazici H, Hekim H. Monozygotic twins concordant for Behçet's syndrome. Arthritis Rheum 1991;34: 1071-2.
12. Gül A, Inanç M, Öcal L, Aral O, Çarin M, Koniçe M. HLA-B51 negative monozygotic twins discordant for Behçet's disease. Br J Rheumatol 1997;36:922-3.
13. Zouboulis CC, Büttner P, Djawari D, et al. HLA-class I antigens in German patients with Adamantiades-Behçet's disease and correlation with clinical manifestations. In: Wechsler B, Godeau P, eds. Behçet's disease. Amsterdam: Excerpta Medica, 1993:175-80.
14. Inaba G. Clinical features of neuro-Behçet's syndrome. In: Lehner T, Barnes CG, eds. Recent advances in Behçet's disease. London: Royal Society of Medicine Services, 1986:235-46.
15. Ehrlich GE. Vasculitis in Behçet's disease. Int Rev Immunol 1997;14: 81-8.
16. Yamashita N, Kaneoka H, Kaneko S, et al. Role of gammadelta T lymphocytes in the development of Behçet's disease. Clin Exp Immunol 1997; 107:241-7.
17. Mochizuki M, Suzuki N, Takeno M, et al. Fine antigen specificity of human gamma delta T cell lines (V gamma 9+) established by repetitive stimulation with a serotype (KTH-1) of a gram-positive bacterium, Streptococcus sanguis. Eur J Immunol 1994;24:1536-43.
18. Sakane T, Suzuki N, Ueda Y, et al. Analysis of interleukin-2 activity in patients with Behçet's disease: ability of T cells to produce and respond to interleukin-2. Arthritis Rheum 1986;29:371-8.
19. Suzuki N, Sakane T, Ueda Y, Tsunematsu T. Abnormal B cell function in patients with Behçet's disease. Arthritis Rheum 1986;29:212-9.
20. Sakane T, Kotani H, Takada S, Tsunematsu T. Functional aberration of T cell subsets in patients with Behçet's disease. Arthritis Rheum 1982; 25:1343-51.
21. Pervin K, Childerstone A, Shinnick T, et al. T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behçet's disease. J Immunol 1993;151:2273-82.
22. Kaneko S, Suzuki N, Yamashita N, et al. Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behçet's disease (BD) in Japan. Clin Exp Immunol 1997;108:204-12.
23. Direskeneli H, Hasan A, Shinnick T, et al. Recognition of B-cell epitopes of the 65 kDa HSP in Behçet's disease. Scand J Immunol 1996; 43:464-71.
24. Stanford MR, Kasp E, Whiston R, et al. Heat shock protein peptides reactive in patients with Behçet's disease are uveitogenic in Lewis rats. Clin Exp Immunol 1994;97:226-31.
25. Hu W, Hasan A, Wilson A, et at. Experimental mucosal induction of uveitis with the 60-kDa heat shock protein-derived peptide 336-351. Eur J Immunol 1998;28:2444-55.
26. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
27. Bang D, Hur W, Lee ES, Lee S. Prognosis and clinical relevance of recurrent oral ulceration in Behçet's disease. J Dermatol 1995;22:926-9.
28. Benamour S, Zeroual B, AJaoui FZ. Joint manifestations in Behçet's disease: a review of 340 cases. Rev Rhum Engl Ed 1998;65:299-307.
29. Serdaroglu P. Behçet's disease and the nervous system. J Neurol 1998; 245:197-205.
30. Hamuryudan V, Yurdakul S, Moral F, et al. Pulmonary arterial aneurysms in Behçet's syndrome: a report of 24 cases. Br J Rheumatol 1994; 33:48-51.
31. Miyachi Y, Taniguchi S, Ozaki M, Horio T. Colchicine in the treatment of the cutaneous manifestations of Behçet's disease. Br J Dermatol 1981;104:67-9.
32. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Mcd 1998;128:443-50.
33. Hamuryudan V, Özyazgan Y, Hizli N, et al. Azathioprine in Behçct's syndrome: effects on long-term prognosis. Arthritis Rheum 1997;40:769-74.
34. Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A. Successful treatment of Behçet disease with pentoxifylline. Ann Intern Med 1996; 124:891-3.
35. O'Duffy JD, Robrtson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. Am J Med 1984;76:75-84.
36. O'Duffy JD, Calamia K, Cohen S, et al. Interferon-alpha treatment of Behçet's disease. J Rneumatol 1998;25:1938 44.
37. Kazokoglu H, Saatci O, Cuhadaroglu H, Eldem B. Long-term effects of cyclophosphamide and colchkine treatment in Behçet's disease. Ann Ophthalmol 1991;23:148-51.
38. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989;1:1093-6.
39. Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 1999;106:586-9.
40. Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behçet disease with systemic Interferon alfa. Arch Dermatol 1998;134:1010-6.
41. Lee KS, Kim SJ, Lee BC, Yoon DS, Lee WJ, Chi HS. Surgical treatment of intestinal Behçet's disease. Yonsei Mcd J 1997;38:455-60.
42. Kotter I, Durk H, Saal J, Fierlbeck G, Pleyer U, Ziehut M. Therapy of Behçet's disease. Ger J Ophthalmol 1996;5:92-7.
43. Akman-Demir G, Baykan-Kurt B, Serdaroglu P, et al. Seven-year follow-up of neurologic involvement in Behçet syndrome. Arch Neural 1996; 53:691-4.